Wegovy Also Known As: The Names, the Medicines and What Actually Differs

The misconception: Ozempic and Wegovy are the same thing

They contain the same molecule, so the claim is understandable. But under UK law they are different licensed medicines. Ozempic (semaglutide 0.5 mg, 1 mg and 2 mg) holds a UK marketing authorisation for type 2 diabetes. Wegovy (semaglutide 2.4 mg injection, and now the 25 mg tablet) holds a separate licence for weight management in adults with obesity or overweight plus a weight-related health condition. That distinction is not a technicality, it determines whether a prescription is lawful, which clinical assessments apply and what safety monitoring goes with it.

The MHRA has been clear on this point, and the NHS medicines guidance for semaglutide lists the two products separately because their licensed indications are separate. A prescriber writing a Wegovy script for weight loss is not prescribing Ozempic. Using Ozempic for weight loss without a specific clinical indication for diabetes would be off-label, which is a very different regulatory position.

The confusion is fuelled partly by media coverage that treats all semaglutide injections as one story, and partly by social media sellers who blur the distinctions deliberately. If you want a thorough rundown of the key things to know about Wegovy before making any decisions, that is a good place to start. If someone is offering you "the Ozempic weight-loss pen", that is a red flag worth taking seriously.

Rybelsus and the Wegovy tablet: the same molecule, different products again

Oral semaglutide adds another layer. Rybelsus tablets (3 mg, 7 mg, 14 mg) are licensed in the UK for type 2 diabetes. On 11 June 2026 the MHRA approved a separate oral product (Wegovy tablets) specifically for weight management, making the UK the first country in Europe to do so. The dosing schedule for Wegovy tablets runs 1.5 mg → 4 mg → 9 mg → 25 mg, titrated monthly by a prescriber. None of those strengths overlap with Rybelsus.

This is not a minor branding choice. The formulations are designed around different patient populations and clinical targets. Someone researching "oral semaglutide for weight loss" and landing on Rybelsus information will find the wrong doses, the wrong licence and the wrong safety framing. Our page on Wegovy and how it works covers the full injection and tablet picture if you want the clinical detail in one place.

One practical point that sets the tablet apart from any injection: no refrigeration is needed. The pen lives in the fridge door; the tablet travels in a pocket or handbag without any storage requirement. For people whose routine makes cold-chain management awkward, that is a genuine difference worth raising with a prescriber.

What these names mean for accessing treatment in the UK

Because Wegovy (injection or tablet) is a prescription-only medicine, the legal route is a consultation with a qualified prescriber who can assess eligibility based on your BMI, health history and any medicines you already take. The licensed weight-management threshold is a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

On the NHS, Wegovy injection is available through specialist weight management services under NICE guidance (TA875). The Wegovy tablet does not yet have a NICE appraisal, so it is currently available through private prescription only. If you are trying to work out which route or product applies to your situation, the clearest next step is a structured clinical conversation rather than cross-referencing brand names online. Our guide to starting Wegovy covers what that process looks like in practice, and our semaglutide overview pulls together the full evidence picture for the molecule across its licensed uses.

It is also worth knowing that a higher-dose Wegovy injection format now exists. The MHRA approved a dedicated 7.2 mg single-dose pen on 14 April 2026, for adults with a BMI of 30 or above. Treatment still begins at 0.25 mg and is titrated upward by the prescriber; the 7.2 mg dose is the ceiling, not the starting point. Whether a specific dose or pen format is available at any given time is confirmed at consultation, not before it.

Checking that a supplier is legitimate before you look further

With multiple brand names circulating across social media and comparison sites, the risk of landing on a seller who conflates them for commercial reasons is real. The MHRA seized around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million in 2025, and in October that year raided the first known UK site manufacturing counterfeit tirzepatide pens. Semaglutide products are equally targeted.

Any pharmacy supplying these medicines in the UK must be registered with the GPhC. You can verify nume's GPhC registration (9012878) on the pharmacy register in seconds. Sellers offering semaglutide products without a prescription, through social media, or at prices that seem implausibly low relative to the market should be reported to the MHRA via the Yellow Card scheme. That tool is for suspected counterfeit sellers as well as side-effect reports.

If you want to understand the differences between available weight-loss treatments before speaking to a clinician, our weight-loss treatment overview sets them out without the brand-name noise. Once you have started treatment, our page on how to tell whether Wegovy is working explains the signs and timelines to look out for. You can also find a practical breakdown of what to keep in mind while taking Wegovy, covering everything from missed doses to lifestyle factors. For anything specific to your circumstances, speak to our prescribers through a free consultation.